Plozasiran is an investigational medication being studied for treating severe hypertriglyceridemia (very high levels of triglycerides in the blood) in adults who are at high risk of developing acute pancreatitis. This medication is designed to help reduce the risk of sudden inflammation of the pancreas by controlling triglyceride levels in the blood.

Severe Hypertriglyceridemia (SHTG) – A metabolic disorder characterized by abnormally high levels of triglycerides (fat molecules) in the blood, specifically exceeding 500 mg/dL. The condition develops when the body cannot effectively break down or remove triglycerides from the bloodstream. SHTG can be inherited genetically or develop due to other health conditions, poor diet, or certain medications. The excess triglycerides can accumulate in various organs throughout the body. This condition often causes symptoms such as recurrent abdominal pain, fatty deposits under the skin, and enlargement of the liver or spleen.

Acute Pancreatitis (AP) – An inflammatory condition where the pancreas becomes suddenly inflamed. The condition occurs when digestive enzymes become activated while still inside the pancreas, causing the organ to begin digesting itself. AP typically causes intense pain in the upper abdomen, which can spread to the back. The inflammation usually develops over a short period, causing symptoms such as nausea, vomiting, and tenderness in the abdomen. The condition can be triggered by various factors, including very high blood triglyceride levels.